Therapy-related myelodysplastic syndrome and myeloid leukemia

Myelodysplastic Syndromes: Pathobiology and Clinical Management, Second Edition

Volumn , Issue , 2008, Pages 173-194

  Godley, Lucy A ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952940983     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Brunning RD, Matutes E, Flandrin G, et al. Acute myeloid leukaemias and myelodysplastic syndromes, therapy related. In: Jaffe ES, Harris NL, Stein H, et al., eds.World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001:89-91.
2. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: Overview report. Genes Chromosomes Cancer 2002; 33:331-345.
3. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003; 102:43-52.
4. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004; 104:822-828.
5. SeedhouseC, Russell N. Advances in the understanding of susceptibility to treatmentrelated acute myeloid leukaemia. Br J Haematol 2007; 137:513-529.
6. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609 C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94:803-807.
7. Bolufer P, Collado M, Barragan E, et al. Profile of polymorphisms of drugmetabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007; 136:590-596.
8. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 2001; 98:11592-11597.
9. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapyrelated leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6:4091-4095.
10. Fern L, Pallis M, Ian Carter G, et al. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 2004; 126:63-71.
11. Guillem VM, Collado M, Terol MJ, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 2007; 21:1413-1422.
12. Sheikhha MH, Tobal K, Liu Yin JA. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002; 117:359-365.
13. Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003; 9:3012-3020.
14. Worrillow L, Smith A, Scott K, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008; 45:142-146.
15. Felix CA, Hosler MR, Provisor D, et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996; 87:4376-4381.
16. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112:741-749.
17. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
18. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66:5104-5110.
19. Bond GL, Menin C, Bertorelle R, et al.MDM2SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006; 43:950-952.
20. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.
21. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-1100.
22. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25:47-54.
23. Maris JM, Wiersma SR, Mahgoub N, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997; 79:1438-1446.
24. Mahgoub N, Taylor BR, Le Beau MM, et al. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 1999; 93:3617-3623.
25. Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene 2006; 25:5875-5884.
26. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292-2302.
27. Le Beau MM, Espinosa R III, Davis EM, et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88:1930-1935.
28. Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A 1997; 94:6948-6953.
29. Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: Bennett JM, ed. The Myelodysplastic Syndromes: Pathobiology and Clinical Management, New York: Marcel Dekker, Inc., 2002:139-176.
30. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326:1745-1751.
31. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986; 105:360-367.
32. Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia:Report from an internationalworkshop. GenesChromosomesCancer 2002; 33:395-400.
33. Slovak ML, Bedell V, Popplewell L, et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 2002; 33:379-394.
34. Coso D, Costello R, Cohen-Valensi R, et al. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann Oncol 1999; 10:362-363.
35. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an intergroup study, cancer and leukemia group B. J Clin Oncol 2002; 20:3878-3884.
36. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105:4573-4575.
37. Martin-Salces M, Canales MA, de Paz R, et al. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab. Leuk Res 2008; 32:199-200.
38. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25:4285-4292.
39. Fenske TS, McMahon C, Edwin D, et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res 2006; 66:5029-5038.
40. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110:719-726.
41. Ebert BL, Pretz J, Bosco J, et al. Abstracts of Papers, 49th National Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2007. Washington, DC: American Society of Hematology, 2007; Abstract #1.
42. Pedersen-Bjergaard J, Christiansen DH, Desta F, et al. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20:1943-1949.
43. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematol Am Soc Hematol Educ Program 2004:80-97.
44. Qian Z, Fernald AA, Godley LA, et al. Expression profiling of CD34 + hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A 2002; 99:14925-14930.
45. Schnittger S, Bacher U, KernW, et al. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML. Leukemia 2007; 21:183-184.
46. Desta F, Christiansen DH, Andersen MK, et al. Activating mutations of JAK2V617 F are uncommon in t-MDS and t-AML and are only observed in atypic cases. Leukemia 2006; 20:547-548.
47. Christiansen DH, Desta F, Andersen MK, et al. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations. Genes Chromosomes Cancer 2007; 46:517-521.
48. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21:1195-1204.
49. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196-205.
50. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007; 25:292-300.
51. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone MarrowTransplant 2007; 39:59-70.
52. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stemcell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24:3604-3610.
53. Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: A large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000; 71:144-152.
54. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993; 7:81-107.
55. Larson RA, Wernli M, Le Beau MM, et al. Short remission durations in therapyrelated leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood 1988; 72:1333-1339.
56. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123-2137.
57. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89:2578-2585.
58. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18:963-971.
59. Hale GA, Heslop HE, Bowman LC, et al. Bone marrow transplantation for therapyinduced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999; 24:735-739.
60. Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37:183-189.
61. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18:120-125.
62. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13:655-664.
63. Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22:2510-2511.